VRTX — VERTEX PHARMACEUTICALS INC / MA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 875320 ·
Last close
$525.73
Market Cap
$133.17B
52W High
$546.17
52W Low
$420.01
ADV30
1,468,462
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,333,900,000 | 2,844,700,000 | 1,268,700,000 | 1,099,800,000 | 27,423,300,000 | 6,143,500,000 | 7,175,400,000 |
| Mar 2026 | 2,986,900,000 | 2,594,100,000 | 1,138,800,000 | 1,031,400,000 | 26,484,400,000 | 5,492,900,000 | 7,122,500,000 |
| Dec 2025 | 3,190,000,000 | 2,724,000,000 | 1,130,300,000 | 1,191,100,000 | 25,643,000,000 | 5,084,800,000 | 6,977,200,000 |
| Sep 2025 | 3,076,400,000 | 2,661,600,000 | 1,238,800,000 | 1,082,900,000 | 24,862,300,000 | 4,939,600,000 | 7,543,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,292,900,000
Investing CF
$-882,800,000
Financing CF
$-2,197,200,000
CapEx
$-496,800,000
Dividends Paid
—
Buybacks
$-2,332,200,000
EPS Diluted TTM
$17.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$15,691,200,000
Inventory
$1,765,100,000
Receivables
$2,134,300,000
ST Investments
$1,708,900,000
EBIT TTM
$5,043,900,000
Pretax Income TTM
$5,274,500,000
Interest Exp TTM
$13,300,000
Analysts
25
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,587,200,512
EBITDA
$5,100,499,968
Free Cash Flow
$2,627,887,616
Enterprise Value
$128,370,778,112
Total Cash
$7,852,400,128
Total Debt
$1,977,600,000
Shares Out
253,300,000
Trailing EPS
$17.03
Book Value
$79.92
ROE
23.5%
ROA
11.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,001,300,000 | 4,554,400,000 | 3,953,200,000 | 25,643,000,000 | 6,977,200,000 | — | 3,631,400,000 |
| Dec 2024 | 11,020,100,000 | -233,400,000 | -535,600,000 | 22,533,200,000 | 6,123,600,000 | — | -492,600,000 |
| Dec 2023 | 9,869,200,000 | 3,780,400,000 | 3,619,600,000 | 22,730,200,000 | 5,149,800,000 | — | 3,537,300,000 |
| Dec 2022 | 8,930,700,000 | 4,249,900,000 | 3,322,000,000 | 18,150,900,000 | 4,238,200,000 | — | 4,129,900,000 |
TTM Snapshot
Revenues TTM
$9,573,800,000
NetIncome TTM
$3,863,100,000
OpCashFlow TTM
$0
Assets (Latest)
$22,533,200,000
Forward EPS
$21.80
Max Pain — expiry 2026-08-21
max pain strike: $492.50 · spot: $516.44 · call oi: 2,528 · put oi: 4,174Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | $130.12B | $63.70 | — |
| NONOF | NOVO NORDISK A S | $143.36B | $43.36 | — |
| PFE | PFIZER INC | $149.96B | $26.31 | — |
| NVO | NOVO NORDISK A S | $153.38B | $46.39 | — |
| SNY | Sanofi | $104.74B | $43.71 | — |
News headlines (Yahoo Finance, 1h cache)
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
2026-08-12 15:02 · Yahoo
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
2026-08-12 01:41 · Yahoo
Vertex (VRTX) Q2 2026 Earnings Call Transcript
2026-08-11 01:29 · Yahoo
Why Vertex Pharma Popped, As A Key Rival Plummeted 92%
2026-08-10 20:04 · Yahoo
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
2026-08-10 15:55 · Yahoo
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
2026-08-10 12:22 · Yahoo
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
2026-08-07 18:20 · Yahoo
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses
2026-08-12 03:41 · Yahoo
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?
2026-08-10 17:18 · Yahoo
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
2026-08-10 19:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.